Sanofi's "star small molecule" protein degrader new drug has been approved for clinical trials in China.
1min read On January 20, the National Medical Products Administration's Center for Drug Evaluation (CDE) officially announced that Sanofi's (SNY.US) newly approved 1st-class new drug SAR444656 has been granted a clinical trial implicit permit, with proposed indications including atopic dermatitis (AD) and purulent sweat glanditis (HS). According to the CDE's website, SAR444656 is a proteasome inhibitor of IRAK4 protein, developed by Kymera Therapeutics and Sanofi. It was listed as one of the top ten "star" small molecules in 2023 by the drug hunter website (drughunter.com). In addition, Sanofi introduced its pipeline of promising new drugs, including SAR444656, at its R&D Day in 2023.According to the ClinicalTrials website, Sanofi is conducting two international multicenter Phase 2 clinical studies to evaluate the efficacy and safety of SAR444656 in treating adult patients with moderate to severe purulent sweat glanditis and moderate to severe atopic dermatitis. The approval of SAR444656's clinical trial in China means that the product will also enter the clinical research stage in China.
